BMS’ Rayze­Bio inks ra­dio­phar­ma deal in prostate can­cer for $350M up­front

Bris­tol My­ers Squibb’s sub­sidiary Rayze­Bio is spend­ing $350 mil­lion up­front to li­cense an ear­ly-stage ra­dio­phar­ma­ceu­ti­cal can­di­date for prostate can­cer from Philochem.

Rayze­Bio will get glob­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER